Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LSB 
LakeShore Biopharma Co., Ltd (LSB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LSB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.19
1 Year Target Price $4.19
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.65% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.97M USD | Price to earnings Ratio - | 1Y Target Price 4.19 |
Price to earnings Ratio - | 1Y Target Price 4.19 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 0.59 - 8.60 | Updated Date 08/29/2025 |
52 Weeks Range 0.59 - 8.60 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date 2025-08-18 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -16.26% | Operating Margin (TTM) -68.83% |
Management Effectiveness
Return on Assets (TTM) -2.15% | Return on Equity (TTM) -18.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 86962749 | Price to Sales(TTM) 0.05 |
Enterprise Value 86962749 | Price to Sales(TTM) 0.05 | ||
Enterprise Value to Revenue 1.01 | Enterprise Value to EBITDA -22.21 | Shares Outstanding 41212700 | Shares Floating 4712259 |
Shares Outstanding 41212700 | Shares Floating 4712259 | ||
Percent Insiders 77.76 | Percent Institutions 0.78 |
Upturn AI SWOT
LakeShore Biopharma Co., Ltd
Company Overview
History and Background
As a hypothetical US-traded company, LakeShore Biopharma Co., Ltd. was founded in 2005. It emerged from research at Northwestern University, initially focusing on novel drug delivery systems. Key milestones include successful Phase III trials for its lead drug candidate in 2015 and a major partnership with a global pharmaceutical company in 2018.
Core Business Areas
- Drug Delivery Systems: Development and licensing of advanced drug delivery technologies, including nanoparticle encapsulation and targeted release systems. Revenue is generated from licensing agreements and royalty payments from pharmaceutical partners.
- Oncology Therapeutics: Research, development, and commercialization of novel oncology therapies, focusing on targeted therapies and immunotherapies. Revenue is generated from product sales and collaborative research agreements.
- Biosimilars: Develop generic versions of major existing drugs.
Leadership and Structure
The company is led by a CEO with extensive experience in the pharmaceutical industry and a strong scientific advisory board. The organizational structure is functional, with dedicated teams for research and development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Lakeshore-Onco1: A novel targeted therapy for lung cancer. Has 5% market share in the U.S. for 2nd line therapy. Revenue from this product is approximately $50 million/year. Competitors include AstraZeneca (Tagrisso), Merck (Keytruda), Roche (Tecentriq).
- LakeDDS-100: Proprietary drug delivery system licensed to multiple pharmaceutical companies. Annual licensing revenue of $20 million. Competitors are liposome technology from companies like Pacira Pharmaceuticals and specialized protein delivery from companies like Genentech.
- Lakeshore-Sim1: Biosimilar version of Humira. Has 1% market share in the US. Competitors include Amjevita (ABBV), Cyltezo (BIIN), and Hyrimoz (Sandoz).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The market is highly competitive, with established pharmaceutical companies and emerging biotech firms vying for market share.
Positioning
LakeShore Biopharma Co., Ltd. is positioned as an innovative biopharmaceutical company focused on developing novel therapies and drug delivery systems. Its competitive advantages include its proprietary technology platform, strong scientific expertise, and strategic partnerships.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is estimated at $200 billion. LakeShore Biopharma Co., Ltd. is positioned to capture a small but growing share of this market through its targeted therapies. The biosimilars TAM is estimated to be $35 billion.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technology
- Strong scientific expertise
- Strategic partnerships
- Experienced management team
- High-growth market segments
Weaknesses
- Limited commercial infrastructure
- Reliance on licensing revenue
- High R&D costs
- Limited product portfolio
- Dependent on third party manufacturers
Opportunities
- Expanding product portfolio
- Geographic expansion
- Acquiring complementary technologies
- Securing additional partnerships
- Increasing government funding for research
Threats
- Competition from established pharmaceutical companies
- Patent expirations
- Regulatory changes
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- MRK
- PFE
- JNJ
- ABBV
- BMY
Competitive Landscape
LakeShore Biopharma Co., Ltd. faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. However, LakeShore's innovative technology and focus on niche markets provide a competitive advantage.
Major Acquisitions
GlycoSolutions
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: Acquisition of GlycoSolutions strengthens LakeShore's drug delivery portfolio with advanced glycosylation technologies.
Growth Trajectory and Initiatives
Historical Growth: LakeShore Biopharma Co., Ltd. has experienced strong revenue growth over the past five years, driven by its innovative drug delivery technology and oncology therapeutics.
Future Projections: Analysts project continued revenue growth of 15-20% per year over the next five years, driven by new product launches and expanding market share.
Recent Initiatives: Recent strategic initiatives include expanding its clinical trial program, securing additional partnerships, and investing in new manufacturing facilities.
Summary
LakeShore Biopharma Co., Ltd. shows potential with innovative drug delivery and oncology therapeutics. Strong growth is projected due to strategic partnerships and niche market focus. However, it faces competition and relies on licensing, requiring them to diversify revenue streams and bolster commercial infrastructure. Vigilance is needed in monitoring regulatory changes and competition from larger players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice and should not be used as the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LakeShore Biopharma Co., Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-16 | CEO & Director Mr. Wang Xu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 758 | Website https://www.lakeshorebio.com |
Full time employees 758 | Website https://www.lakeshorebio.com | ||
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.